Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
RLAY on Nasdaq
Shares outstanding
171,717,172
Price per share
$8.46
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
166,222,637
Total reported value
$867,515,589
% of total 13F portfolios
0%
Share change
-4,551,651
Value change
-$18,690,235
Number of holders
196
Price from insider filings
$8.46
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 9.9% +26% $88,740,000 +$19,053,000 17,000,000 +27% Commodore Capital LP 30 Sep 2025
Point72 Asset Management, L.P. 7.8% +35% $50,152,476 +$13,993,047 13,445,704 +39% Point72 Asset Management, L.P. 30 Jun 2025
BlackRock, Inc. 6.1% -30% $32,882,558 -$13,928,338 10,308,012 -30% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.5% -24% $32,454,284 -$9,430,469 9,379,851 -23% The Vanguard Group 30 Jun 2025

As of 30 Sep 2025, 196 institutional investors reported holding 166,222,637 shares of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY). This represents 97% of the company’s total 171,717,172 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SB INVESTMENT ADVISERS (UK) LTD 16% 27,904,963 0% 1.1% $145,663,907
Commodore Capital LP 9.9% 17,000,000 +27% 4.3% $88,740,000
Point72 Asset Management, L.P. 8.6% 14,773,676 +9.9% 0.17% $77,118,589
BlackRock, Inc. 8% 13,759,382 -1.4% 0% $71,823,974
Casdin Capital, LLC 6.6% 11,341,381 -0.5% 4.9% $59,202,009
VANGUARD GROUP INC 5.5% 9,395,744 +0.17% 0% $49,045,785
Bellevue Group AG 4.9% 8,345,610 +1.4% 0.91% $43,564,084
TANG CAPITAL MANAGEMENT LLC 4.7% 8,068,058 0% 1.6% $42,115,263
STATE STREET CORP 3% 5,065,990 -2.6% 0% $26,444,468
Nextech Invest, Ltd. 2.2% 3,846,409 0% 3.1% $20,078,255
GEODE CAPITAL MANAGEMENT, LLC 1.8% 3,054,586 -5.4% 0% $15,947,600
Kynam Capital Management, LP 1.7% 2,887,014 0% 1.1% $15,070,213
DIMENSIONAL FUND ADVISORS LP 1.4% 2,482,950 -11% 0% $12,960,818
MPM BIOIMPACT LLC 1.3% 2,282,680 0% 2% $11,915,590
GOLDMAN SACHS GROUP INC 1.1% 1,868,871 -3.4% 0% $9,755,506
TCG Crossover Management, LLC 1.1% 1,810,351 0.46% $9,450,032
MORGAN STANLEY 1% 1,764,096 +24% 0% $9,208,581
Alphabet Inc. 0.91% 1,568,753 0% 0.34% $8,188,891
AQR CAPITAL MANAGEMENT LLC 0.76% 1,301,036 +20% 0% $6,791,407
BANK OF AMERICA CORP /DE/ 0.7% 1,195,843 -9.4% 0% $6,242,302
Balyasny Asset Management L.P. 0.68% 1,174,971 0.01% $6,133,349
NORTHERN TRUST CORP 0.68% 1,165,434 +0.29% 0% $6,083,565
BAKER BROS. ADVISORS LP 0.68% 1,160,117 0% 0.04% $6,055,811
PRICE T ROWE ASSOCIATES INC /MD/ 0.66% 1,137,681 -60% 0% $5,940,000
TWO SIGMA ADVISERS, LP 0.65% 1,124,300 -1.4% 0.01% $5,868,846

Institutional Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 683,885 $5,771,622 +$1,650,883 $8.46 6
2025 Q3 166,222,637 $867,515,589 -$18,690,235 $5.22 196
2025 Q2 170,927,354 $591,366,333 +$36,190,035 $3.46 203
2025 Q1 162,665,545 $426,190,863 -$16,276,230 $2.62 205
2024 Q4 163,889,986 $675,297,060 -$42,360,167 $4.12 197
2024 Q3 163,415,012 $1,156,675,796 +$253,277,512 $7.08 193
2024 Q2 126,697,163 $826,050,230 -$42,426,305 $6.52 171
2024 Q1 132,236,260 $1,097,561,545 +$24,572,655 $8.30 182
2023 Q4 127,244,702 $1,400,985,578 -$17,110,979 $11.01 176
2023 Q3 130,456,510 $1,097,122,997 -$2,918,566 $8.41 169
2023 Q2 129,294,786 $1,623,964,520 -$20,848,790 $12.56 159
2023 Q1 131,039,866 $2,156,444,291 +$53,163,179 $16.47 155
2022 Q4 128,192,171 $1,915,159,649 +$58,936,160 $14.94 163
2022 Q3 123,551,085 $2,763,964,560 +$25,518,843 $22.37 153
2022 Q2 120,596,011 $2,019,993,086 +$124,571,798 $16.75 137
2022 Q1 113,095,261 $3,384,210,971 +$67,735,824 $29.93 133
2021 Q4 110,982,949 $3,407,692,692 +$588,792,014 $30.71 128
2021 Q3 91,778,622 $2,894,965,132 +$74,331,777 $31.53 132
2021 Q2 89,144,608 $3,261,742,353 +$138,052,473 $36.59 124
2021 Q1 85,493,244 $2,955,555,198 -$171,240,328 $34.57 135
2020 Q4 87,701,562 $3,644,892,889 +$108,159,345 $41.56 115
2020 Q3 84,683,348 $3,603,495,710 +$3,603,495,710 $42.59 94